Fox Rothschild advised HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, in its $102 million series D financing. The round was led by Alpha Wave Ventures, a world leader in growth stage investments, with participation from new investors Amzak Health and HealthQuest Capital, and existing investors Johnson & Johnson Innovation - JJDC, Inc. (JJDC), Venture Investors, Lumira Ventures, Yonjin Venture, the State of Wisconsin Investment Board, and others.
Histotripsy is a novel form of focused ultrasound that uses high amplitude, very short pulses to create a “bubble cloud” that is designed to mechanically destroy and liquefy targeted liver tumors. These bubble clouds form and collapse in microseconds, creating mechanical forces strong enough to destroy tissue at cellular and sub-cellular levels in a non-invasive and non-thermal method. Histotripsy offers a promising alternative to treatments such as surgery, radiation and chemotherapy, which often have significant side effects.
Please refer to HistoSonics’ press release for additional information on HistoSonics and its series D financing.
HistoSonics and this transaction were also highlighted in the Wall Street Journal and Minneapolis Star Tribune.
Fox partners Brett Hanson and Tom Moran led the Fox team advising HistoSonics.
Original source can be found here.